期刊文献+

双-多特异性纳米抗体的构建形式 被引量:1

Bi- and multi-specific nanobody construction formats
原文传递
导出
摘要 双特异性抗体(双抗)可以同时特异性结合2种不同抗原,已成为抗体工程领域研究的热点。这些研究主要集中在癌症治疗方面,虽疗效显著但还未达到临床最佳状态。由于双抗有2条重链和2条轻链,因而极易出现错配。为解决这一问题,研究者设计出许多不同的双抗形式,例如串联单链抗体、双可变结构域抗体或使用“knobs-into-holes”方式构建的抗体,但仍不能得到最优的双抗。纳米抗体是目前已知最小的全功能抗体,具有许多优异的理化特性,为构建双一多特异性抗体提供了一种全新的途径。 Bi-specific antibodies (BsAbs) recognizing two different antigens simultaneously have become hot spot in antibody engineering recently. Most BsAbs are developed for cancer immunotherapy but only sub-optimal effects have been achieved so far. The major bottlenecks for developing BsAb are the heavy and light chain pairing problems. Many alternative BsAb formats are explored for overcoming these problems, including tandem single chain fragment variable, dual-variable domains-Ig, and knobs- into-holes. Despite the extensive efforts, more robust formats remain highly needed to construct better BsAbs. Heavy chain-only nanobodies are the smallest fully functional antibody and a novel building block for constructing hi- and multi-specific antibodies.
作者 庄文超 林兆新(综述) 李福胜(审校) Zhuang Wenchao;Lin Zhaoxin;Li Fusheng(Antibody Research and Development,Sysvax Inc.,Beijing 100011,China)
出处 《国际生物制品学杂志》 CAS 2018年第5期244-248,共5页 International Journal of Biologicals
关键词 双-多特异性抗体 纳米抗体 构建形式 Bi- and multi-specific antibodies Nanobody Construction format
  • 相关文献

参考文献2

二级参考文献89

  • 1GARBER K. Bispecific antibodies rise again[ J]. Nat Rev Drug Discov,2014, 13(11) : 799 -801. 被引量:1
  • 2SPASEVSKA I. An outlook on bispecific antibodies: methods of production and therapeutic benefits [ M ]. France:Ens de Lyon, 2013, 1-7. 被引量:1
  • 3TOPP MS, KUFER P, GOKBUGET N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy- refractoryminimal residual disease in B-lineage acute lymphoblas- tic leukemia patients results in high response rate and prolonged leukemia-free survival [ J]. J Clini Oncol, 2011, 29 ( 18 ) : 2493 - 2498. 被引量:1
  • 4TOPP MS, GKBUGET N, STEIN AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B- precursor acute lymphoblastic leukaemia: a muhicentre, single- arm, phase2 study[J]. Lancet Oncol, 2015, 16(1):57-66. 被引量:1
  • 5KONTERMANN RE, BRINKMANN U- Bispecific antibodies [J]. Drug Discovery Today, 2015, 20(7): 838-847. 被引量:1
  • 6ZEIDLER R, REISBACH G, WOLLENBERG B, et al. Simulta- neous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing [J]. Jlmmunol, 1999, 163(3): 1246-1252. 被引量:1
  • 7HEISS MM, MURAWA P, KORALEWSKI P, et al. The trifune- tional antibody catumaxomab for the treatment of malignant ascites due to epithelial eancer: Results of a prospective randomized phase II/III trial[ J ]. Int J Cancer J Int Cancer, 2010, 127 (9) : 2209 - 2221. 被引量:1
  • 8BUHMANN R, MICHAEL S, JUERGEN H, et al. Immunother- apy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in re- lapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation : study protocol of an investigator-driven, open-la- bel, non-randomized, uncontrolled, dose-escalating Phase I/II- trial[J]. J Translat Med, 2013, 11:160. 被引量:1
  • 9RIDGWAY JB, PRESTA LG, CARTER P. ' Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodime- rization[J]. ProteinEng, 1996, 9(7): 617 -621. 被引量:1
  • 10CARTER P. Bispecific human IgG by design [ J]. J Immunol Met, 2001, 248(1 -2): 7-15. 被引量:1

共引文献13

同被引文献18

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部